J. Ewing, Diffuse endothelioma of bone, Proc NY Pathol Soc, vol.12, p.17, 1921.

H. W. Hense, S. Ahrens, M. Paulussen, and M. Lehnert, Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies, Klin Pediatr, vol.211, pp.271-276, 1999.

C. A. Stiller, S. S. Bielack, G. Jundt, and E. Steliarova-foucher, Report from the Automated Childhood Cancer Information System project, Eur J Cancer, vol.42, pp.2124-2159, 1978.

Y. S. Lau, I. E. Adamopoulos, A. Sabokbar, H. Giele, C. Gibbons et al., Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma, Br J Cancer, vol.96, pp.1716-1738, 2007.

R. Jaffe, M. Santamaria, E. J. Yunis, N. H. Tannery, R. M. Agostini et al., The neuroectodermal tumor of bone, Am J Surg Pathol, vol.8, pp.885-98, 1984.

A. L. Folpe, E. M. Chand, J. R. Goldblum, and S. W. Weiss, Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics, Am J Surg Pathol, vol.25, pp.1061-1067, 2001.

W. A. May, M. L. Gishizky, S. L. Lessnick, L. B. Lunsford, B. C. Lewis et al., Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation, Proc Natl Acad Sci, vol.90, pp.5752-5758, 1993.

F. Nakatani, K. Tanaka, R. Sakimura, Y. Matsumoto, T. Matsunobu et al., Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein, J Biol Chem, vol.278, pp.15105-15120, 2003.

L. Dauphinot, D. Oliveira, C. Melot, T. Sevenet, N. Thomas et al., Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression, Oncogene, vol.20, pp.3258-65, 2001.

M. D. Cohen, E. M. Bugaieski, M. Haliloglu, P. Faught, and A. R. Siddiqui, Visual presentation of the staging of pediatric solid tumors, Radiographic, vol.16, pp.523-568, 1996.

S. J. Cotterill, S. Ahrens, M. Paulussen, . Hf, P. A. Voûte et al., Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group, J Clin Oncol, vol.18, pp.3108-3122, 2000.

S. Bouralexis, D. M. Findlay, and A. Evdokiou, Death to the bad guys: targeting cancer via Apo2L/TRAIL, Apoptosis, vol.10, pp.35-51, 2005.

I. Holen and C. M. Shipman, Role of osteoprotegerin (OPG) in cancer, Clin Sci (Lond), vol.110, pp.279-91, 2006.

L. Zhang and B. Fang, Mechanisms of resistance to TRAIL-induced apoptosis in cancer, Cancer Gene Ther, vol.12, pp.228-265, 2005.

N. B. Liabakk and T. Espevik, Monoclonal antibodies against TRAIL, Vitam Horm, vol.12, pp.65-79, 2004.

F. A. Kruyt, TRAIL and cancer therapy, Cancer Lett, vol.263, pp.14-25, 2008.

G. S. Wu, TRAIL as a target in anti-cancer therapy, Cancer Lett, vol.285, pp.1-5, 2009.

A. W. Tolcher, M. Mita, N. J. Meropol, M. Von-mehren, A. Patnaik et al., Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1, J Clin Oncol, vol.25, pp.1390-1395, 2007.

S. Leong, R. B. Cohen, D. L. Gustafson, C. J. Langer, D. R. Camidge et al., an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study, J Clin Oncol, vol.27, pp.4413-4434, 2009.

R. Plummer, G. Attard, S. Pacey, L. Li, A. Razak et al., Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers, Clin Cancer Res, vol.13, pp.6187-94, 2007.

H. A. Wakelee, A. Patnaik, B. I. Sikic, M. Mita, N. L. Fox et al., Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors, Ann Oncol, vol.21, pp.376-81, 2010.

C. Adams, K. Totpal, D. Lawrence, S. Marsters, R. Pitti et al., Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5, Cell Death Differ, vol.15, pp.751-61, 2008.

H. U. Kontny, K. H?-ammerle, R. Klein, P. Shayan, C. L. Mackall et al., Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis, Cell Death Differ, vol.8, pp.506-520, 2001.

N. Mitsiades, V. Poulaki, C. Mitsiades, and M. Tsokos, Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2, Cancer Res, vol.61, pp.2704-2716, 2001.

G. Picarda, F. Lamoureux, L. Geffroy, P. Delepine, T. Montier et al., Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival, Clin Cancer Res, vol.16, pp.2363-74, 2010.

B. M. Kurbanov, L. F. Fecker, C. C. Geilen, W. Sterry, and J. Eberle, Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4, Oncogene, vol.26, pp.3364-77, 2007.

S. Wang and W. S. El-deiry, TRAIL and apoptosis induction by TNF-family death receptors, Oncogene, vol.22, pp.8628-8661, 2003.

X. D. Zhang, A. Franco, K. Myers, C. Gray, T. Nguyen et al., Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICEinhibitory protein expression to TRAIL-induced apoptosis of melanoma, Cancer Res, vol.59, pp.2747-53, 1999.

F. L. Graham, J. Smiley, W. C. Russell, and R. Nairn, Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J Gen Virol, vol.36, pp.59-74, 1977.

E. Menoret, P. Gomez-bougie, A. Geffroy-luseau, S. Daniels, P. Moreau et al., Mcl-1L cleavage is involved in TRAIL-R1-and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells, Blood, vol.108, pp.1346-52, 2006.

V. Trichet, C. Benezech, C. Dousset, M. C. Gesnel, and M. Bonneville, Breathnach R. Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown, J Immunol, vol.177, pp.6129-6165, 2006.

X. F. Qin, D. S. An, I. S. Chen, and D. Baltimore, Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5, Proc Natl Acad Sci, vol.100, pp.183-191, 2003.

J. H. Naismith and S. R. Sprang, Modularity in the TNF-receptor family, Trends Biochem Sci, vol.23, pp.74-83, 1998.

J. Mongkolsapaya, J. M. Grimes, N. Chen, X. N. Xu, D. I. Stuart et al., Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation, Nat Struct Mol Biol, vol.6, pp.1048-53, 1999.

A. Sali and T. L. Blundell, Comparative protein modelling by satisfaction of spatial restraints, J Mol Biol, vol.234, pp.779-815, 1993.

Z. H. Jiang and J. Y. Wu, Alternative splicing and programmed cell death, Proc Soc Exp Biol Med, vol.220, pp.64-72, 1999.

G. R. Screaton, J. Mongkolsapaya, X. Xu, A. E. Cowper, A. J. Mcmichael et al., TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL, Curr Biol, vol.7, pp.693-699, 1997.

L. Galligan, D. B. Longley, M. Mcewan, T. R. Wilson, K. Mclaughlin et al., Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP, Mol Cancer Ther, vol.4, pp.2026-2062, 2005.

D. B. Longley, T. R. Wilson, M. Mcewan, W. L. Allen, U. Mcdermott et al., c-FLIP inhibits chemotherapy-induced colorectal cancer cell death, Oncogene, vol.25, pp.838-886, 2006.

T. R. Wilson, K. M. Mclaughlin, M. Mcewan, H. Sakai, K. M. Rogers et al., c-FLIP: a key regulator of colorectal cancer cell death, Cancer Res, vol.67, pp.5754-62, 2007.

A. M. Waterhouse, J. B. Procter, D. Martin, M. Clamp, and G. J. Barton, Jalview Version 2-a multiple sequence alignment editor and analysis workbench, Mol Cancer Res Gaëlle Picarda, vol.25, pp.336-346, 2009.

A. Functional, New Short Isoform of Death Receptor 4 in Ewing's Updated version